CONMED Corp. Stock
CONMED Corp. Stock
The CONMED Corp. stock is trending slightly upwards today, with an increase of €0.20 (0.500%) compared to yesterday's price.
Currently there is a rather positive sentiment for CONMED Corp. with 4 Buy predictions and 1 Sell predictions.
With a target price of 47 € there is a slightly positive potential of 15.76% for CONMED Corp. compared to the current price of 40.6 €.
So far the community has only identified positive things for CONMED Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of CONMED Corp. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | 0.500% | 2.732% | 25.333% | -12.558% | 7.429% | -64.860% | -67.863% |
| Haemonetics Corp. | 2.840% | 5.797% | 7.353% | - | 6.569% | - | - |
| Bio-Rad Labs Inc. A | -0.480% | 6.562% | 10.604% | 30.681% | 10.818% | -24.392% | -51.966% |
| Penumbra Inc | 0.290% | 0.649% | 1.160% | 42.456% | 4.730% | 0.360% | 24.332% |
Comments
CONMED (CNMD) had its "underperform" rating reaffirmed by Bank of America Corporation. They now have a $40.00 price target on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
News
CONMED Q2 Earnings Call Highlights
Key Points
- Interested in CONMED Corporation? Here are five stocks we like better.
- CONMED delivered better-than-expected Q2 results: Organic sales rose 6%, adjusted EPS increased 20% to $1.38
